filmov
tv
FDA flags small risk of neurological disorder after Johnson and Johnson vaccine
Показать описание
Federal health officials flagged "a small possible risk" of developing a nervous system disorder after receiving Johnson and Johnson's COVID-19 vaccine on Monday, after the CDC identified a very rare pattern of Guillain-Barré syndrome in some recipients of the shot. As Nikki Battiste reports, there have been about 100 cases, mostly in older men. Dr. Amesh Adalja, an infectious disease expert and senior scholar at Johns Hopkins University Bloomberg School of Public Health, joins CBSN to discuss vaccine concerns and a recent spike in new infections.
FDA flags small risk of neurological disorder after Johnson and Johnson vaccine
FDA flags 'small possible risk' from Johnson and Johnson vaccine
FDA Safety Report Type Flag Requirement for FAERS Submissions
FDA Monitoring Rare Condition In 100 People With J&J Vaccine
FDA warns of increased risk of rare neurological syndrome associated with Johnson & Johnson vacc...
FDA Announces Regulatory Plan to Shift Trajectory of Tobacco-related Disease and Death
Using the Least Burdensome Flag Pilot Program from FDA
FDA warns of possible rare neurological side effect with Janssen vaccine
Pfizer to discuss booster shot with FDA; Children at very low risk of COVID-19 – Weekly News 13 July...
FDA Inspections of Compounding Outsourcing Facilities
FDA Warns About Risk Involving Rare Nerve Syndrome And Johnson & Johnson Vaccine
FDA warns of possible link between Johnson & Johnson vaccine and Guillain-Barre syndrome
Consulting Companies and FDA Limitations Panel Discussion
The Disturbing History of Aspartame
FDA Inspections: the Good the Bad and the Ugly
New Breast Cancer Screening Recommendation from the FDA
Dr. Jason Fung: Financial Conflicts of Interests and the End of Evidence-Based Medicine
FDA Issues New Warning For J&J Vaccine Over Rare Side Effect
FDA approval of REZDIFFRA (resmetirom) for NASH/MASH treatment
FDA issues new warning on rare autoimmune disorder linked to J&J vaccine
2019 CCTS FDA Conference - Defining and Managing Risks using Corrective Action
FDA Guidance on Manufacturing During COVID-19 and High Absenteeism
Introduction to FDA’s Office of Trade and Global Partnerships
FDA Webinar on the Food Traceability Final Rule
Комментарии